Calamos Advisors LLC Biogen Inc. Transaction History

Calamos Advisors LLC

$15.7 Billion
Q2 2024

A detailed history of Calamos Advisors LLC transactions in Biogen Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 37,455 shares of BIIB stock, worth $7.29 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

37,455

Previous 38,822 3.52%

Holding current value

$7.29 Million

Previous $8.37 Million 3.72%

% of portfolio

0.06%

Previous 0.06%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	SELL	$190.52 - $236.72 $260,440 - $323,596	-1,367 Reduced 3.52%	37,455 $8.68 Million
Q1 2024 May 08, 2024	SELL	$212.02 - $267.71 $206,931 - $261,284	-976 Reduced 2.45%	38,822 $8.37 Million
Q4 2023 Jan 31, 2024	SELL	$222.59 - $267.94 $115,746 - $139,328	-520 Reduced 1.29%	39,798 $10.3 Million
Q1 2023 May 03, 2023	SELL	$256.56 - $292.34 $1.29 Million - $1.47 Million	-5,041 Reduced 11.11%	40,318 $11.2 Million
Q4 2022 Jan 25, 2023	SELL	$252.44 - $306.72 $2.02 Million - $2.46 Million	-8,020 Reduced 15.02%	45,359 $0
Q2 2022 Aug 01, 2022	BUY	$187.54 - $223.02 $269,682 - $320,702	1,438 Added 2.77%	53,379 $10.9 Million
Q1 2022 May 03, 2022	BUY	$193.77 - $244.14 $1.34 Million - $1.69 Million	6,923 Added 15.38%	51,941 $10.9 Million
Q4 2021 Feb 01, 2022	BUY	$223.92 - $287.77 $390,292 - $501,583	1,743 Added 4.03%	45,018 $10.8 Million
Q3 2021 Oct 26, 2021	BUY	$282.99 - $369.05 $1.08 Million - $1.41 Million	3,818 Added 9.68%	43,275 $12.2 Million
Q2 2021 Jul 22, 2021	BUY	$259.0 - $414.71 $1.7 Million - $2.72 Million	6,547 Added 19.89%	39,457 $13.7 Million
Q1 2021 Apr 12, 2021	BUY	$242.95 - $284.63 $232,746 - $272,675	958 Added 3.0%	32,910 $9.21 Million
Q4 2020 Jan 27, 2021	SELL	$236.26 - $355.63 $316,824 - $476,899	-1,341 Reduced 4.03%	31,952 $7.82 Million
Q3 2020 Oct 26, 2020	SELL	$264.77 - $305.71 $728,647 - $841,313	-2,752 Reduced 7.63%	33,293 $9.45 Million
Q2 2020 Jul 27, 2020	SELL	$258.66 - $342.55 $564,654 - $747,786	-2,183 Reduced 5.71%	36,045 $9.64 Million
Q1 2020 Apr 28, 2020	SELL	$268.85 - $341.04 $830,477 - $1.05 Million	-3,089 Reduced 7.48%	38,228 $12.1 Million
Q4 2019 Jan 15, 2020	SELL	$220.06 - $304.07 $262,311 - $362,451	-1,192 Reduced 2.8%	41,317 $12.3 Million
Q3 2019 Oct 21, 2019	BUY	$217.44 - $243.88 $749,515 - $840,654	3,447 Added 8.82%	42,509 $9.9 Million
Q2 2019 Aug 07, 2019	SELL	$219.29 - $241.72 $7.43 Million - $8.19 Million	-33,902 Reduced 46.46%	39,062 $9.14 Million
Q1 2019 Apr 12, 2019	SELL	$216.71 - $338.96 $4.26 Million - $6.67 Million	-19,664 Reduced 21.23%	72,964 $17.2 Million
Q4 2018 Jan 24, 2019	BUY	$278.5 - $352.75 $7.4 Million - $9.37 Million	26,572 Added 40.23%	92,628 $27.9 Million
Q3 2018 Oct 22, 2018	BUY	$293.51 - $383.83 $9.66 Million - $12.6 Million	32,896 Added 99.2%	66,056 $23.3 Million
Q2 2018 Jul 17, 2018	BUY	$257.52 - $306.91 $515,555 - $614,433	2,002 Added 6.43%	33,160 $9.62 Million
Q1 2018 Apr 13, 2018	BUY	$260.13 - $367.91 $353,256 - $499,621	1,358 Added 4.56%	31,158 $8.53 Million
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $169,202 - $189,519	-550 Reduced 1.81%	29,800 $9.49 Million
Q3 2017 Oct 25, 2017	BUY	$281.15 - $329.69 $434,376 - $509,371	1,545 Added 5.36%	30,350 $9.5 Million
Q2 2017 Aug 09, 2017	BUY	N/A	28,805	28,805 $7.82 Million

Others Institutions Holding BIIB

# of Institutions

1,050

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $28B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Calamos Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Calamos Advisors LLC with notifications on news.

Account

Calamos Advisors LLC Biogen Inc. Transaction History